Tejon Ranch Co.
NYSE:TRCConglomerates
-$0.06 today
- Market cap
- $465.26M
- Beta
- 0.59
- P/E (TTM)
- 296.5
- EPS (TTM)
- $0.06
Volume 0.26M
Average 0.09M
TRC Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Tejon Ranch Co.NYSE: TRC
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures declines year over year
Q1 FY2026 capital expenditures of $9.65M (cash outflow) fell 63.7% year over year, ahead of the -73.1% change in trailing-twelve-month capital expenditures. Sequentially, it fell 63.7% from the prior quarter. Over 3 fiscal years it compounded at +44.5% a year.
Context
- Capital expenditures amounted to 143.6% of revenue in FY2025, down 14.2 pp from a year earlier.
- Capital expenditures grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -63.7% holds above the trailing-twelve-month pace of -73.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (71.22M) USD
- Year-over-year change
- -7.7%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (71.22M) | -7.7% |
| FY2024 | 2024-12-31 | (66.11M) | -141.6% |
| FY2023 | 2023-12-31 | (27.36M) | -16.0% |
| FY2022 | 2022-12-31 | (23.59M) | -1.3% |
| FY2021 | 2021-12-31 | (23.29M) | — |
Capital Expenditures vs competitors
How TRC compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -73.1% is the 8th highest of 9, against a peer median of -33.9%.
- Capital expenditures amounts to 41.9% of revenue for TRC, versus a peer median of 3.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | $181.17M USD | -23.1% | +24.2% | 11.7% | |
| LTM Mar 2026 | $38.4M USD | +80.5% | +38.6% | 4.4% | |
| LTM Mar 2026 | $36.32M USD | -41.5% | -9.7% | 2.0% | |
| LTM Mar 2026 | $30.16M USD | -84.0% | -5.3% | 13.3% | |
| LTM Mar 2026 | $21.31M USD | -73.1% | +44.5% | 41.9% | |
SRTAStrata Critical Medical, Inc. | LTM Mar 2026 | $13.18M USD | -62.4% | +147.1% | 5.2% |
| LTM Apr 2026 | $7.92M USD | -42.1% | — | 1.5% | |
| LTM Mar 2026 | $6.36M USD | -5.4% | +32.0% | 0.8% | |
| LTM Mar 2026 | £555.43K GBP | — | -47.9% | — | |
| LTM Mar 2026 | $73K USD | -26.3% | -21.8% | 0.4% | |
| Peer median (excluding TRC) | — | -33.9% | +9.4% | 3.2% | |
Competitors are the stored peer set for TRC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 5.34M | 15.81M | 3.27M | 2.69M | 71K |
| Depreciation & Amortization | 4.59M | 4.63M | 4.81M | 4.89M | 6.01M |
| Deferred Income Tax | 1.13M | 2.87M | 1.12M | 784K | 782K |
| Stock-Based Compensation | 4.27M | 2.88M | 3.25M | 4.18M | 1.71M |
| Change in Working Capital | (96K) | 1.84M | (4.61M) | 3.21M | (2.8M) |
| Accounts Receivables | (814K) | 3.24M | (4.48M) | 261K | 2.27M |
| Inventory | 0 | 1.05M | 0 | 0 | 0 |
| Accounts Payables | 0 | (3.24M) | 0 | 0 | 0 |
| Other Working Capital | 718K | 786K | (132K) | 2.95M | (5.07M) |
| Other Non-Cash Items | (12.43M) | (19.49M) | 5.82M | (1.43M) | 356K |
| Operating Cash Flow | 2.82M | 8.53M | 13.66M | 14.31M | 6.13M |
| Capital Expenditures | (23.29M) | (23.59M) | (27.36M) | (66.11M) | (71.22M) |
| Acquisitions (Net) | (2.9M) | (800K) | (4.5M) | (346K) | (2.28M) |
| Purchases of Investments | (14.59M) | (63.88M) | (132.32M) | (74M) | (32.39M) |
| Sales of Investments | 6.25M | 41.14M | 137.8M | 92.61M | 31.64M |
| Other Investing Activities | 19.88M | 45.25M | 12.38M | 22.1M | 11.95M |
| Investing Cash Flow | (14.65M) | (1.89M) | (14M) | (25.75M) | (62.31M) |
| Debt Repayment | (4.3M) | (2.63M) | (2.42M) | 19M | 27M |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | (2.73M) | 0 | (206K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.79M) | 942K | (4.45M) | 0 | (569K) |
| Financing Cash Flow | (6.09M) | (4.42M) | (6.87M) | 18.79M | 26.43M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (17.92M) | 2.22M | (7.21M) | 7.36M | (29.74M) |
| Free Cash Flow | (20.48M) | (15.06M) | (13.71M) | (51.79M) | (65.09M) |
Tejon Ranch Co.
NYSE:TRC
Intrinsic Alpha fair value
Locked
Current Price
$17.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.